Liver carcinogenesis: From naughty chemicals to soothing fat and the surprising role of NRF2

Carcinogenesis

Volumn 37, Issue 6, 2016, Pages 541-546

  Karin, Michael ^a,b   Dhar, Debanjan ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TOXIC SUBSTANCE; TRANSCRIPTION FACTOR NRF2; DIETHYLNITROSAMINE; NFE2L2 PROTEIN, HUMAN; PROTECTIVE AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ENDOPLASMIC RETICULUM STRESS; INFLAMMATION; LIPID DIET; LIVER; LIVER CANCER; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; METABOLISM; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; STEM CELL; ADVERSE EFFECTS; ANIMAL; CARCINOMA, HEPATOCELLULAR; CHEMICALLY INDUCED; COMPLICATION; DISEASE MODEL; HEPATITIS; HUMAN; LIVER NEOPLASMS; MUTATION; PATHOLOGY; PHYSIOLOGY;

ANIMALS; CARCINOMA, HEPATOCELLULAR; DIET, HIGH-FAT; DIETHYLNITROSAMINE; DISEASE MODELS, ANIMAL; HEPATITIS; HUMANS; LIVER NEOPLASMS; MICE; MUTATION; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; PROTECTIVE AGENTS;

EID: 84973659356     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgw060     Document Type: Article

References (58)

1. Williams, G.M. (1983) Epigenetic effects of liver tumor promoters and implications for health effects. Environ. Health Perspect., 50, 177-183.
2. Vogelstein, B. et al. (2013) Cancer genome landscapes. Science, 339, 1546-1558.
3. Nachman, M.W. et al. (2000) Estimate of the mutation rate per nucleotide in humans. Genetics, 156, 297-304.
4. Zilfou, J.T. et al. (2009) Tumor suppressive functions of p53. Cold Spring Harb. Perspect. Biol., 1, a001883.
5. Burkhart, D.L. et al. (2008) Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat. Rev. Cancer, 8, 671-682.
6. Sun, W. et al. (2010) Functional mechanisms for human tumor suppressors. J. Cancer, 1, 136-140.
7. Swann, J.B. et al. (2007) Immune surveillance of tumors. J. Clin. Invest., 117, 1137-1146.
8. Laursen, L. (2014) A preventable cancer. Nature, 516, S2-S3.
9. Xu, R. et al. (2008) Wilson disease and hepatocellular carcinoma. Gastroenterol. Hepatol. (NY), 4, 438-439.
10. Kowdley, K.V. (2004) Iron, hemochromatosis, and hepatocellular carcinoma. Gastroenterology, 127, S79-S86.
11. Humphries, C. (2014) Sex differences: luck of the chromosomes. Nature, 516, S10-S11.
12. Naugler, W.E. et al. (2007) Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science, 317, 121-124.
13. Ryerson, A.B. et al. (2016) Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer. Cancer, 122, 1312-1337.
14. Caldwell, S.H. et al. (2004) Obesity and hepatocellular carcinoma. Gastroenterology, 127, S97-S103.
15. Calle, E.E. et al. (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N. Engl. J. Med., 348, 1625-1638.
16. Schulze, K. et al. (2015) Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat. Genet., 47, 505-511.
17. Kan, Z. et al. (2013) Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Res., 23, 1422-1433.
18. Villanueva, A. et al. (2014) Liver cancer in 2013: mutational landscape of HCC-the end of the beginning. Nat. Rev. Clin. Oncol., 11, 73-74.
19. Maeda, S. et al. (2005) IKKbeta couples hepatocyte death to cytokinedriven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell, 121, 977-990.
20. Pikarsky, E. et al. (2004) NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature, 431, 461-466.
21. Greten, F.R. et al. (2004) IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell, 118, 285-296.
22. Sakurai, T. et al. (2008) Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogen-induced compensatory proliferation and liver tumorigenesis. Cancer Cell, 14, 156-165.
23. Fausto, N. et al. (2003) The role of hepatocytes and oval cells in liver regeneration and repopulation. Mech. Dev., 120, 117-130.
24. He, G. et al. (2013) Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling. Cell, 155, 384-396.
25. Fujii, T. et al. (2010) Mouse model of carbon tetrachloride induced liver fibrosis: histopathological changes and expression of CD133 and epidermal growth factor. BMC Gastroenterol., 10, 79.
26. Uehara, T. et al. (2014) The DEN and CCl4-induced mouse model of fibrosis and inflammation-associated hepatocellular carcinoma. Curr. Protoc. Pharmacol., 66, 14.30.1-14.30.10.
27. Farber, E. (1990) Clonal adaptation during carcinogenesis. Biochem. Pharmacol., 39, 1837-1846.
28. Rabes, H.M. (1983) Development and growth of early preneoplastic lesions induced in the liver by chemical carcinogens. J. Cancer Res. Clin. Oncol., 106, 85-92.
29. International Working Party (1995) Terminology of nodular hepatocellular lesions. Hepatology, 22, 983-993.
30. Hytiroglou, P. et al. (2007) Hepatic precancerous lesions and small hepatocellular carcinoma. Gastroenterol. Clin. N. Am., 36, 867-87, vii.
31. Paolini, M. et al. (1991) Is clonal adaptation a product of evolution over the millennia? Biochem. Pharmacol., 42, 457-458.
32. Weglarz, T.C. et al. (2000) Hepatocyte transplantation into diseased mouse liver. Kinetics of parenchymal repopulation and identification of the proliferative capacity of tetraploid and octaploid hepatocytes. Am. J. Pathol., 157, 1963-1974.
33. Font-Burgada, J. et al. (2015) Hybrid periportal hepatocytes regenerate the injured liver without giving rise to cancer. Cell, 162, 766-779.
34. Finkin, S. et al. (2015) Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma. Nat. Immunol., 16, 1235-1244.
35. He, G. et al. (2010) Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. Cancer Cell, 17, 286-297.
36. El-Serag, H.B. (2012) Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology, 142, 1264-1273.e1.
37. Kimer, N. et al. (2012) Antiviral therapy for prevention of hepatocellular carcinoma in chronic hepatitis C: systematic review and meta-analysis of randomised controlled trials. BMJ Open, 2:e001313.
38. Chang, M.H. et al. (2009) Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J. Natl Cancer Inst., 101, 1348-1355.
39. Di Bisceglie, A.M. (2009) Hepatitis B and hepatocellular carcinoma. Hepatology, 49, S56-S60.
40. Sun, B. et al. (2012) Obesity, inflammation, and liver cancer. J. Hepatol., 56:704-713.
41. Park, E.J. et al. (2010) Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell, 140, 197-208.
42. Cave, M. et al. (2010) Toxicant-associated steatohepatitis in vinyl chloride workers. Hepatology, 51, 474-481.
43. Wahlang, B. et al. (2013) Toxicant-associated steatohepatitis. Toxicol. Pathol., 41, 343-360.
44. Joshi-Barve, S. et al. (2015) Alcoholic, nonalcoholic, and toxicant-associated steatohepatitis: mechanistic similarities and differences. CMGH Cell. Mol. Gastroenterol. Hepatol., 1, 356-367.
45. Nugent, C. et al. (2007) Evaluation and management of obesity-related nonalcoholic fatty liver disease. Nat. Clin. Pract. Gastroenterol. Hepatol., 4, 432-441.
46. Wree, A. et al. (2013) From NAFLD to NASH to cirrhosis-new insights into disease mechanisms. Nat. Rev. Gastroenterol. Hepatol., 10, 627- 636.
47. Michelotti, G.A. et al. (2013) NAFLD, NASH and liver cancer. Nat. Rev. Gastroenterol. Hepatol., 10, 656-665.
48. Starley, B.Q. et al. (2010) Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology, 51, 1820-1832.
49. Nakagawa, H. et al. (2014) ER stress cooperates with hypernutrition to trigger TNF-dependent spontaneous HCC development. Cancer Cell, 26, 331-343.
50. Umemura, A. et al. (2016) p62, upregulated during preneoplasia, induces hepatocellular carcinogenesis by maintaining survival of stressed HCC-initiating cells. Cancer Cell, in press.
51. Sanz, L. et al. (2000) The atypical PKC-interacting protein p62 channels NF-kappaB activation by the IL-1-TRAF6 pathway. EMBO J., 19, 1576- 1586.
52. Komatsu, M. et al. (2012) p62/SQSTM1/A170: physiology and pathology. Pharmacol. Res., 66, 457-462.
53. Denk, H. et al. (2006) Are the Mallory bodies and intracellular hyaline bodies in neoplastic and non-neoplastic hepatocytes related? J. Pathol., 208, 653-661.
54. Menon, S. et al. (2012) Chronic activation of mTOR complex 1 is sufficient to cause hepatocellular carcinoma in mice. Sci. Signal., 5, ra24.
55. Zhong, Z. et al. (2016) NF-kappaB restricts inflammasome activation via elimination of damaged mitochondria. Cell, 164, 896-910.
56. Suzuki, T. et al. (2013) Toward clinical application of the Keap1-Nrf2 pathway. Trends Pharmacol. Sci., 34, 340-346.
57. Shibata, T. et al. (2014) Exploration of liver cancer genomes. Nat. Rev. Gastroenterol. Hepatol., 11, 340-349.
58. Totoki, Y. et al. (2014) Trans-ancestry mutational landscape of hepatocellular carcinoma genomes. Nat. Genet., 46, 1267-1273.